Industry Satellite Symposia
Switch To Module
ESMO Congress 2021 - Conference Calendar
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Digital Evaluations
Everything
Everything
Session Title
Session Number
Presentation Title
Presentation Number
Author
Presenter
Chair
Filter By
Day
Select All
Deselect All
Fri, 17.09.2021
12
Sat, 18.09.2021
11
Sun, 19.09.2021
12
Mon, 20.09.2021
11
Tue, 21.09.2021
11
Room
Select All
Deselect All
Channel 3
14
Channel 4
15
Channel 5
13
Channel 6
15
Session Type
Select All
Deselect All
Industry Satellite Symposium
57
Presentation Type
Select All
Deselect All
Invited Speaker
57
Presentation Topic
Select All
Deselect All
General interest
57
Cancel
Clear
Search
Advanced Search
Sign in
Scheduled sessions
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Final Programme PDF
Browsing Over 57 Sessions
Sort By
Session Number
Upcoming First
Relevance
Session Number
Session Datetime
Takeda - Illuminating the Path Forward in EGFR Exon20 Insertion+ mNSCLC: Unmet Needs and the Evolving Treatment Landscape
(ID 121)
Time
18:45 - 20:15
AstraZeneca - Emerging Agents in Breast Cancer Care
(ID 155)
Time
17:35 - 19:05
Amgen - Precision therapy in NSCLC: the dawn of KRAS G12C inhibition
(ID 115)
Time
10:30 - 12:00
PER Global, LLC - Leveraging Antibody-Drug Conjugates in Cancer Care: Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors
(ID 150)
Time
10:30 - 12:00
Pfizer Oncology - Expert Perspectives in ALK+NSCLC: a round table discussion
(ID 110)
Time
08:45 - 09:45
Sanofi Genzyme - Optimizing Immuno-oncology in NSCLC: What Do We Know and Where Should We Go?
(ID 144)
Time
18:45 - 20:15
Novartis - Unmet needs in oncogene-driven NSCLC: how do we close the gap?
(ID 105)
Time
10:30 - 12:00
Novartis - Staying on Track: Translating Evidence to Practice in Melanoma
(ID 139)
Time
10:30 - 12:00
Servier - The clinical value of mIDH1 inhibition in cholangiocarcinoma
(ID 100)
Time
08:45 - 10:15
Incyte - Making Precision Medicine a Reality for Patients with Cholangiocarcinoma
(ID 133)
Time
18:45 - 19:58
BeiGene - A New Breath in Lung Cancer
(ID 128)
Time
10:30 - 12:00
Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
(ID 123)
Time
08:45 - 09:55